MP44-10 TREATMENT TRENDS OF SMALL RENAL MASSES IN PATIENTS OF ADVANCED AGE

You have accessJournal of UrologyKidney Cancer: Evaluation and Staging II1 Apr 2015MP44-10 TREATMENT TRENDS OF SMALL RENAL MASSES IN PATIENTS OF ADVANCED AGE Shan Dong, Jonathan E. Kiechle, Simon P. Kim, Robert Abouassaly, Edward E. Cherullo, Lee Ponsky, Cary P. Gross, Nilay D. Shah, and Hui Zhu Shan DongShan Dong More articles by this author , Jonathan E. KiechleJonathan E. Kiechle More articles by this author , Simon P. KimSimon P. Kim More articles by this author , Robert AbouassalyRobert Abouassaly More articles by this author , Edward E. CherulloEdward E. Cherullo More articles by this author , Lee PonskyLee Ponsky More articles by this author , Cary P. GrossCary P. Gross More articles by this author , Nilay D. ShahNilay D. Shah More articles by this author , and Hui ZhuHui Zhu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1552AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Radical nephrectomy (RN) and partial nephrectomy (PN) are accepted treatment modalities for patients with small renal masses (SRMs). The benefits of resection are lower in patients with limited life expectancy given the competing risks of death. We sought to determine national trends of management of SRMs in patients of advanced age. METHODS We used the National Cancer Database (NCDB) to identify patients aged greater than 80 years old and diagnosed with SRM's (T1a) renal cell carcinoma (RCC) from 2001 to 2011. The primary outcomes were active treatment (partial nephrectomy, radical nephrectomy and local ablative therapy) and observation. Chi-square analysis was used to analyze treatment trends over time. RESULTS We identified 7,397 patients aged greater than 80 years old with clinical T1a SRMs. Overall, 79.7% of patients had active treatment (RN, PN, local ablation) in 2001. This nadired at 68.5% in 2009, and then increased to 70.5% in 2011. The use of expectant management remained relatively stable at 22.6% in 2001 to 26.9% in 2011 (See Figure). CONCLUSIONS Despite increasing evidence of the low risk of progression and metastasis from SRMs, expectant management of these tumors remains relatively low and stable. Given this population's limited life expectancy, informed decision making about the risks and benefits of treatment is needed on an individual basis. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e530 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shan Dong More articles by this author Jonathan E. Kiechle More articles by this author Simon P. Kim More articles by this author Robert Abouassaly More articles by this author Edward E. Cherullo More articles by this author Lee Ponsky More articles by this author Cary P. Gross More articles by this author Nilay D. Shah More articles by this author Hui Zhu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...